News

Kuter describes several studies investigating aspects of rilzabrutinib which were presented at the ISTH 2025 Congress.

Findings showed GLP-1 RAs reduced the risk of overall dementia, particularly Alzheimer’s disease and non-vascular dementias, compared with metformin.

Study finds monthly HAE attacks dropped from 54% to 9.8% after 3 years of lanadelumab, with improved quality of life and reduced severity.

Fudim discusses his experiences in prescribing GLP-1 receptor agonists, as well as his opinions regarding remote patient monitoring.

The National Institute for Health and Care Excellence endorses betula verrucosa for long-term relief from severe birch tree allergies, such as allergic rhinitis or conjunctivitis.

Study findings showed IBS patients with self-perceived gluten sensitivity reacted similarly to gluten, wheat, and sham challenges.

This case–control study compared sleep quality, risk of obstructive sleep apnoea, and quality of life between those with psoriasis and healthy controls.

Genentech reveals mixed results for astegolimab in COPD trials, highlighting challenges in treatment options for this serious respiratory disease.

This interview with Saakshi Khattri, MD, highlights recent findings on deucravacitinib as an oral therapy for patients living with psoriatic arthritis (PsA).

A new study showed that cashew-induced anaphylaxis mostly affects children under 5 years, often from tiny amounts that are under a teaspoon.

In CKD patients with COVID-19, prior vaccination significantly reduced risks of major adverse kidney events and mortality, especially with ≥ 3 doses.

Nearly 13 million people received DAA treatment in the last 10 years, representing 21% of the starting 62 million people with chronic HCV and 30% of the target population.

Isaacs and Bellini discuss the highlights of the Endocrine Society’s annual meeting, from upcoming treatments to public education.

Patients with hereditary angioedema who switched to donidalorsen saw significantly fewer attacks and improved disease control. The FDA decision expected in August 2025.

The announcement of this NDA submission to the FDA highlights icotrokinra, a first-in-class investigational targeted oral peptide for plaque psoriasis.

In this interview segment, Hamade highlights the potential benefits of an oral drug like deucravacitinib in psoriasis and psoriatic arthritis.

A 2-step direct amoxicillin challenge safely ruled out penicillin allergy in low-risk pregnant patients, offering a faster alternative to skin testing.

An audio recap of the top 5 stories in healthcare news from the week of 07/07-07/13.

This analysis examined the connection between atopic dermatitis severity and frequency of flares, along with which variables potentially predict flares.

Psychiatrists at the 2025 So Cal Psych Conference shared evidence-based tools and therapies to improve mental health outcomes for new mothers.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and designations as well as new clinical trial data, in this week's essential news roundup.

Isaacs, Bellini, and Levy discuss a currently recruiting trial investigating CGM metrics in pregnant individuals with type 1 diabetes.

Steger discussed the importance of tailoring diet strategies to patients with type 2 diabetes.

Shah discusses the stagnation of the T1D treatment landscape and the potential progress that GLP-1 RA research could present.

This interview with Hamade highlights some of the most notable takeaways regarding deucravacitinib’s safety among patients with psoriasis.

Host Brendon Neuen is joined by guests Tor Biering-Sørensen and Kristoffer Skaarup to discuss NUDGE-CKD and implementation trial design.

Announced by Aldeyra Therapeutics, Inc. on July 17, the FDA also assigned a PDUFA target action date of December 16, 2025.

Philis-Tsimikas emphasized the impact of nonmedical factors on health and how clinicians can be cognizant of them in their patient management.